Peptide Comparison
LarazotidevsBPC-157
Restore your intestinal barrier and protect against gluten damage
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
At a Glance
Quick
comparison
Dose Range
Larazotide
250 mcg–1000 mcg mcg
BPC-157
250–500 mcg
Frequency
Larazotide
Once daily
BPC-157
Once daily
Administration
Larazotide
Oral (capsule or tablet)
BPC-157
Subcutaneous injection
Cycle Length
Larazotide
Ongoing/indefinite
BPC-157
4-6 weeks
Onset Speed
Larazotide
Moderate (1-2 weeks)
BPC-157
Moderate (1-2 weeks)
Evidence Level
Larazotide
Strong human trials (Phase 3 or FDA approved)
BPC-157
Strong preclinical (extensive animal studies)
Efficacy
Benefit
ratings
Intestinal Barrier Protection
Celiac Disease Management
Safety & Tolerability
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compound
specifications
Larazotide
Molecular Formula
C34H59N9O12
Molecular Weight
785.9 g/mol
Half-Life
Unknown - acts primarily as local intestinal barrier regulator rather than systemic drug
Bioavailability
Orally administered; acts locally on intestinal epithelium with minimal systemic absorption
CAS Number
206899-25-6
BPC-157
Molecular Formula
C62H98N16O22
Molecular Weight
1419.53 g/mol
Half-Life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS Number
137525-51-0
Protocols
Dosing
tiers
Larazotide
BPC-157
Applications
Best
suited for
Larazotide
Managing celiac disease symptoms despite strict gluten avoidance
Larazotide is particularly well-suited for individuals focused on managing celiac disease symptoms despite strict gluten avoidance. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing accidental gluten exposure damage
Larazotide is particularly well-suited for individuals focused on reducing accidental gluten exposure damage. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Restoring digestive comfort and nutrient absorption
Larazotide is particularly well-suited for individuals focused on restoring digestive comfort and nutrient absorption. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting intestinal healing and barrier function
Larazotide is particularly well-suited for individuals focused on supporting intestinal healing and barrier function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Side
effects
Larazotide
Common
- Headache
- Nausea
- Abdominal Cramping
- Fatigue
Uncommon
- Transient Diarrhea
Serious
- Allergic Reaction
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Research Status
Safety
& evidence
Larazotide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Not FDA approved
Safety Overview
Larazotide (ALX-0061, AT-1001) is a synthetic tight-junction regulator that improved intestinal barrier function in Phase 2 celiac disease trials with favorable safety. The mechanism—zonula occludens-1 modulation—is specific to epithelial tight junctions without broad immunosuppression. Gastrointestinal side effects (nausea, diarrhea, abdominal pain) occur in 10-20% of patients but are typically mild and resolve with dose adjustment or continued exposure. FDA feedback on Phase 3 trials indicated efficacy trends but required additional manufacturing and clinical data before approval consideration.
Contraindications
- xKnown hypersensitivity to larazotide or any component
- xSevere gastrointestinal obstruction
- xActive untreated infections (may require monitoring)
- xPregnancy and breastfeeding (limited safety data)
BPC-157
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- xPregnancy
- xBreastfeeding
- xActive cancer
- xHistory of cancer
Decision Guide
Which is
right for you?
Choose Larazotide if...
- Managing celiac disease symptoms despite strict gluten avoidance
- Reducing accidental gluten exposure damage
- Restoring digestive comfort and nutrient absorption
- Supporting intestinal healing and barrier function
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health